Merz (Merz Pharma GmbH & Co. KGaA) is a privately held healthcare company headquartered in Frankfurt am Main, Germany. The company focuses on the research, development, and GMP manufacturing of pharmaceuticals and medical-aesthetic products, with operations spanning medical aesthetics and therapeutics.
Merz’s portfolio includes hyaluronic acid dermal fillers (Belotero), botulinum toxin type A for aesthetic and therapeutic indications (Xeomin/Bocouture), and calcium hydroxylapatite injectables (Radiesse). Its products serve dermatology, plastic surgery, aesthetic medicine, and neurology specialties. Merz operates a global network of development and production sites, including facilities in Germany, and distributes its products worldwide through the Merz Aesthetics and Merz Therapeutics divisions.
Also known as Merz Pharma.
chemXplore tracks 1 project involving Merz.
Merz's role on them: Owner.
Japan expands XEOMIN label to two focal dystonias, adding to existing spasticity and sialorrhea indications.
Merz opens a new filler plant, while Oncotec unveils a robot-controlled filling line and visual inspection system, marking significant investments and expansions at Dessau BioPharmaPark.
By country, the most active first. active / all projects
